Table 4 Clinical trials about STING agonists
Agent | First posted data | Route of delivery | Co-therapy | Conditions | Status | Phases | Estimated/Actual Enrollment | First Posted Data | NCT Number |
|---|---|---|---|---|---|---|---|---|---|
GSK3745417 | 2022/6/21 | i.v. | Alone | Leukemia, myeloid, acute | Not yet recruiting | I | 72 | 2022/6/21 | NCT05424380 |
2019/2/18 | i.v. | Alone and combined with dostarlimab | Neoplasms | Recruiting | I | 300 | 2019/2/18 | NCT03843359 | |
TAK-500 | 2021/10/7 | i.v. | Alone and combined with a checkpoint inhibitor pembrolizumab | Pancreatic cancer, hepatocellular cancer, squamous cell cancer (SCC), mesothelioma, non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, esophageal cancer | Recruiting | I | 106 | 2021/10/7 | NCT05070247 |
TAK-676 | 2021/5/10 | i.v. | Alone and combined with pembrolizumab following radiotherapy | Carcinoma, non-small-cell lung, triple-negative breast neoplasms, squamous cell carcinoma of head and neck | Recruiting | I | 65 | 2021/5/10 | NCT04879849 |
2020/6/9 | i.v. | Alone and combined with pembrolizumab following radiotherapy | Solid neoplasms | Recruiting | I | 288 | 2020/6/9 | NCT04420884 | |
SNX281 | 2020/10/30 | i.v. | Alone and combined with a checkpoint inhibitor Pembrolizumab | Advanced solid tumor, advanced lymphoma | Recruiting | I | 134 | 2020/10/30 | NCT04609579 |
SB 11285 | 2019/9/20 | i.v. | Alone and combined with Atezolizumab | Melanoma and head and neck squamous cell carcinoma and solid tumor | Recruiting | I | 110 | 2019/9/20 | NCT04096638 |
CDK-002 | 2020/10/19 | i.t. | Alone | Advanced solid tumor | Active, not recruiting | I/II | 27 | 2020/10/19 | NCT04592484 |
BI 1387446 | 2019/11/1 | i.t. | Alone and combined with Ezabenlimab | Neoplasms | Recruiting | I | 120 | 2019/11/1 | NCT04147234 |
BMS-986301 | 2019/5/21 | i.m., or i.i. or i.v. | Alone and combined with Nivolumab and Ipilimumab | Advanced solid cancers | Recruiting | I | 190 | 2019/5/21 | NCT03956680 |
E7766 | 2019/9/30 | intravesical injection | Alone | Urinary bladder neoplasms | Withdrawn | I | 0 | 2019/9/30 | NCT04109092 |
2019/10/30 | i.t. | Alone | Lymphoma and advanced solid tumors | Recruiting | I | 120 | 2019/10/30 | NCT04144140 | |
IMSA101 | 2019/7/15 | i.t. | Alone and combined with an immune checkpoint inhibitor | Solid tumor, adult | Recruiting | I /II | 115 | 2019/7/15 | NCT04020185 |
MK-1454(Ulevostinag) | 2020/1/7 | i.t. | Alone and combined with Pembrolizumab (MK-3476) | Head and neck squamous cell carcinoma (HNSCC) | Active, not recruiting | II | 200 | 2020/1/7 | NCT04220866 |
2017/1/4 | i.t. | Alone and combined with Pembrolizumab (MK-3475) | Solid tumors and lymphoma | Completed | I | 157 | 2017/1/4 | NCT03010176 | |
SYNB1891 | 2019/11/18 | i.t. | Alone and combined with Atezolizumab | Metastatic solid neoplasm, lymphoma | Recruiting | I | 70 | 2019/11/18 | NCT04167137 |
MK-2118 | 2017/8/15 | i.t. or s.c. | Alone and combined with Pembrolizumab (MK-3475) | Solid tumor and lymphoma | Active, not recruiting | I | 160 | 2017/8/15 | NCT03249792 |
ADU-S100 | 2019/5/3 | i.t. | Alone | Metastatic head and neck cancer, recurrent head and neck cancer | Terminated | II | 16 | 2019/5/3 | NCT03937141 |
2017/6/1 | i.t. | Alone and combined with anti-PD-1 antibody PDR001 | Solid tumors and lymphomas | Terminated | I | 106 | 2017/6/1 | NCT03172936 | |
2016/2/5 | i.t. | Alone and combined with ipilimumab | Advanced/metastatic solid tumors or lymphomas | Terminated | I | 47 | 2016/2/5 | NCT02675439 | |
DMXAA | 2009/3/18 | i.v. | Alone | Solid tumors | Completed | I | 63 | 2009/3/18 | NCT00863733 |
2009/3/5 | i.v. | Alone | Refractory tumors | Completed | I | 15 | 2009/3/5 | NCT00856336 | |
2009/1/30 | n.s. | Alone and combined with carboplatin and paclitaxel | Non-small cell lung cancer | Completed | I /II | 105 | 2009/1/30 | NCT00832494 | |
2004/5/20 | i.v. | Alone | Unspecified adult solid tumor, protocol specific | Completed | I | 3 | 2004/5/20 | NCT00003697 | |
2011/1/28 | n.s. | Alone | Advanced or recurrent solid tumors | Completed | I | 9 | 2011/1/28 | NCT01285453 | |
2008/4/21 | i.v. | Combined with carboplatin and paclitaxel | Non-small cell lung cancer | Terminated | III | 1285 | 2008/4/21 | NCT00662597 | |
2008/8/20 | i.v. | Combined with Docetaxel | Non-small cell lung cancer | Terminated | III | 900 | 2008/8/20 | NCT00738387 | |
2011/9/2 | n.s. | Combined with Fluvoxamine in core Phase, and combined with either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination in Extension Phase | Solid tumors | Terminated | I | 17 | 2011/9/2 | NCT01299415 | |
2011/2/7 | n.s. | Combined with standard chemotherapy | Solid tumor malignancies | Terminated | I | 54 | 2011/2/7 | NCT01290380 | |
2009/12/14 | i.v. | Combined with cetuximab, carboplatin, and paclitaxel | Tumors | Withdrawn | I | 0 | 2009/12/14 | NCT01031212 | |
2010/2/19 | i.v. | Combined with docetaxel | Urothelial carcinoma | Withdrawn | II | 0 | 2010/2/19 | NCT01071928 | |
2010/1/27 | i.v. | Combined with Carboplatin, Paclitaxel and Vadimezan | Lung cancer | Completed | II | 17 | 2010/1/27 | NCT01057342 | |
2005/5/25 | i.v. | Combined with docetaxel | Prostate cancer | Completed | II | 70 | 2005/5/25 | NCT00111618 | |
2011/1/19 | n.s. | Alone | Histologically proven and radiologically confirmed solid tumors | Terminated | I | 5 | 2011/1/19 | NCT01278849 | |
2011/1/19 | i.v. | Alone | Metastatic cancer | Terminated | I | 7 | 2011/1/19 | NCT01278758 | |
2008/5/7 | i.v. | Combined with paclitaxel and carboplatin | Non-small cell lung cancer | Completed | I | 15 | 2008/5/7 | NCT00674102 | |
2011/2/18 | i.v. | Alone | Advanced solid tumors | Terminated | I | 7 | 2011/2/18 | NCT01299701 | |
2010/11/15 | i.v. | Combined with paclitaxel plus carboplatin or docetaxel | Metastatic cancer with impaired renal function, metastatic cancer with normal renal function | Terminated | I | 27 | 2010/11/15 | NCT01240642 |
